|Bid||0.00 x 900|
|Ask||0.00 x 800|
|Day's Range||42.12 - 43.41|
|52 Week Range||14.56 - 52.95|
|PE Ratio (TTM)||N/A|
|Earnings Date||Oct 31, 2018 - Nov 5, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||41.50|
NEW YORK, NY / ACCESSWIRE / August 15, 2018 / U.S. equities snapped losses on Tuesday, as panic over Turkey’s currency eased and market participants focused on upbeat corporate earnings and strong economic ...
SOUTH PLAINFIELD, N.J., Aug. 10, 2018 /PRNewswire/ -- PTC Therapeutics, Inc. (PTCT) today announced that on August 6, 2018 it approved non-statutory stock options to purchase an aggregate of 170,200 shares of its common stock to 27 new employees. The awards were made pursuant to the NASDAQ inducement grant exception as a component of the new hires' employment compensation. The inducement grants were approved by PTC's Compensation Committee on August 6, 2018 and are being made as an inducement material to each employee's acceptance of employment with the Company in accordance with NASDAQ Listing Rule 5635(c)(4).
PTC Therapeutics (PTCT) delivered earnings and revenue surprises of 75.00% and -1.56%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the South Plainfield, New Jersey-based company said it had a loss of 21 cents. Losses, adjusted for amortization costs, were 9 cents per share. The biopharmaceutical company posted ...
Entered into agreement to acquire Agilis Biotherapeutics In-licensed LATAM commercial rights to Tegsedi™ (inotersen) and Waylivra™ (volanesorsen) EC approval of Translarna™ label expansion to children ...
NEW YORK, NY / ACCESSWIRE / August 7, 2018 / PTC Therapeutics, Inc. (NASDAQ: PTCT ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 7, 2018 at 4:30 PM Eastern Time. ...
TEGSEDI has received marketing authorization approval from the European Commission (EC) for the treatment of stage 1 or stage 2 polyneuropathy in adult patients with hereditary transthyretin amyloidosis (hATTR amyloidosis). TEGSEDI is also the subject of a pending new drug application in the U.S. and Canada.
SOUTH PLAINFIELD, N.J. , July 26, 2018 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the Company will host a webcast conference call to report its second quarter 2018 financial ...
Today, Biogen (BIIB) announced its earnings results for the second quarter of fiscal 2018. The company’s sales and earnings came in ahead of Wall Street estimates. Biogen’s spinal muscular atrophy drug, Spinraza, registered sales of $423 million in Q2 2018, which almost doubled compared to the $203 million sales reported in Q2 2017.
PTC Therapeutics (PTCT) generated revenues of $56.1 million in the first quarter, compared to $26.5 million in the first quarter of 2017. PTC Therapeutics’ Emflaza was launched in May 2017, which has driven the company’s revenue growth.
On July 19, PTC Therapeutics (PTCT) entered into an agreement to acquire Agilis Biotherapeutics. This acquisition is expected to include an upfront payment of $50.0 million in cash and ~$150.0 million in PTC Therapeutics common stock. The acquisition of Agilis Biotherapeutics by PTC Therapeutics is expected to close during the third quarter.
SOUTH PLAINFIELD, N.J., July 24, 2018 /PRNewswire/ -- PTC Therapeutics, Inc. (PTCT) today announced the publication of data in Muscle & Nerve comparing the efficacy and safety of deflazacort and prednisone/prednisolone from the placebo arm of the ACT DMD study. The results demonstrated a clinically differentiated benefit of deflazacort over prednisone/prednisolone in slowing disease progression as measured using physical function endpoints and the time to delay loss of ambulation. Duchenne muscular dystrophy patients treated with deflazacort had notably less decline from baseline in 6-minute walk distance at Week 48 than those treated with prednisone/prednisolone.
NEW YORK, NY / ACCESSWIRE / July 20, 2018 / U.S. indexes ended their five day winning streak, which was spurred by strong corporate earnings, as losses from the financial sector dragged markets lower on ...
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on July 19) Bio-Rad Laboratories, Inc. (NYSE: BIO ) Champions Oncology ...
LONDON, UK / ACCESSWIRE / July 20, 2018/ If you want a free Stock Review on RIOT sign up now at www.wallstequities.com/registration. On Thursday, July 19, 2018, the NASDAQ Composite, the Dow Jones Industrial Average, and the S&P 500 edged lower at the closing bell. Taking into consideration yesterday’s market sentiment, WallStEquities.com assessed the following Biotechnology equities this morning: Prothena Corp. PLC (NASDAQ: PRTA), PTC Therapeutics Inc. (NASDAQ: PTCT), Pulmatrix Inc. (NASDAQ: PULM), and Riot Blockchain Inc. (NASDAQ: RIOT).
PTC Therapeutics (ptct) said Thursday afternoon that it plans to acquire gene-therapy startup Agilis Biotherapeutics for $200 million plus incentives, and shares spiked higher. PTC said the five-year-old company has a promising biologics candidate that seeks to treat Aromatic L-Amino Acid Decarboxylase, or AADC, deficiency, a rare disorder of the central nervous system. "Based on multiyear data from initial clinical studies with the AADC gene therapy treatment candidate, PTC plans to submit a Biologics License Application (BLA) to the FDA in 2019," the company stated.
SOUTH PLAINFIELD, N.J., July 19, 2018 /PRNewswire/ -- PTC Therapeutics, Inc. (PTCT) today announced that it has entered into an agreement to acquire Agilis Biotherapeutics, Inc., a biotechnology company advancing an innovative gene therapy platform for rare monogenic diseases that affect the central nervous system (CNS). The transaction was approved by the Boards of both companies. "The addition of the gene therapy platform transforms PTC and aligns with our vision of being a leader in the treatment of rare disorders," said Stuart W. Peltz, Ph.D., Chief Executive Officer, PTC Therapeutics, Inc. "We are impressed with the clinical results shown by the AADC program and are excited with the potential to quickly bring this therapy to patients.
PTC Therapeutics (PTCT) needs investors to pay close attention to the stock based on moves in the options market lately.
SOUTH PLAINFIELD, N.J. , July 9, 2018 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ:PTCT) today announced the presentation of data from the Translarna (ataluren) Phase II Study 030 demonstrating that ...
NEW YORK, June 26, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Church ...